Health policy: Me-too drugs with limited benefits - the tale of regorafenib for HCC

Nat Rev Clin Oncol. 2017 Nov;14(11):653-654. doi: 10.1038/nrclinonc.2017.100. Epub 2017 Jul 18.

Authors

Bishal Gyawali¹, Vinay Prasad²

Affiliations

¹ Institute of Cancer Policy, King's College London, Guy's Hospital Campus, Great Maze Pond Road, London SE1 9RT, UK.
² Division of Hematology Oncology in the Knight Cancer Institute; at the Department of Public Health and Preventive Medicine; and at the Center for Health Care Ethics Oregon at the Health and Sciences University, 3181 SW Sam Jackson Park Road, Portland, Oregon 97239, USA.

PMID: 28719584
DOI: 10.1038/nrclinonc.2017.100

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Agents / adverse effects
Antineoplastic Agents / therapeutic use*
Carcinoma, Hepatocellular / drug therapy*
Drug Approval / methods*
Drug and Narcotic Control / methods
Evidence-Based Medicine / methods
Evidence-Based Medicine / standards
Humans
Liver Neoplasms / drug therapy*
Phenylurea Compounds / adverse effects
Phenylurea Compounds / therapeutic use*
Pyridines / adverse effects
Pyridines / therapeutic use*
Research Design

Substances

Antineoplastic Agents
Phenylurea Compounds
Pyridines
regorafenib